A successful 2007 paves the way for future of Nycomed

NycomedIn 2007 Nycomed increased adjusted EBITDA by 31.0% compared to last year to a total of € 1,222.2 million. The strong performance was accompanied in the fourth quarter by major advancements in the US out-licensing efforts that materialised in early 2008. The full year results benefited from increased sales, especially from high-margin products as well as a significant reduction in costs.

Net turnover increased by € 103.0 million or 3.0% to € 3.497.4 million in 2007, up from € 3,394.4 million during 2006. Net turnover during the fourth quarter 2007 decreased by € 20.3 million from € 883.5 million in 2006 to € 863.2 million during the same period in 2007, a 2.5% decline.

"The past year was Nycomed’s most successful year so far. Financially we have delivered a premium performance, and the integration of Altana Pharma is well ahead of plan. We are building a best-in-class, mid-sized healthcare company that is ready for the future and well positioned to take advantage of growth opportunities", said Håkan Björklund, Nycomed's Chief Executive Officer.

"In the fourth quarter of 2007 we finalised a couple of agreements that are proof to our growth strategy - among others, the acquisition of Bradley Pharmaceuticals was successfully closed in early 2008, as were agreements with Sepracor and Baxter International in the United States. Our markets in Latin America and Russia/CIS as well as in Southern and Eastern Europe continued to grow at very satisfactory rates. And our substantial increase in adjusted EBITDA demonstrates our ability to focus on high-efficiency performance", he continued.

About Nycomed
Nycomed is a privately owned pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. The company is active in a range of therapeutic areas. Its key products are aimed at gastroenterology, pain management, osteoporosis, respiratory diseases and tissue management. New products are sourced both from our own research and from business partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide. The combined group employs over 11,500 people. In 2007, it had annual sales of € 3.5 billion and an adjusted EBITDA of € 1.2 billion. For more information visit www.nycomed.com.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...